nam/aidsmap, Published: 26 January 2016
Two statisticians involved in the PROUD and iPrEx trials of pre-exposure prophylaxis (PrEP) warn that future trials to test new PrEP drugs and formulations may be extremely difficult to design.
David Dunn of the UK Medical Research Council and David Glidden of the University of California, San Francisco say that statisticians will need to choose and analyse their trial population very carefully if they wish to be able to demonstrate meaningful results.
Read more here